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ABSTRACT
Myeloid-derived suppressor cells (MDSC) have been described in inflammatory 
bowel disease (IBD), but their role in the disease remains controversial. We sought 
to define the effect of granulocytic MDSC-derived exosomes (G-MDSC exo) in dextran 
sulphate sodium (DSS)-induced murine colitis. G-MDSC exo-treated mice showed 
greater resistance to colitis, as reflected by lower disease activity index, decreased 
inflammatory cell infiltration damage. There was a decrease in the proportion of Th1 
cells and an increase in the proportion of regulatory T cells (Tregs) in mesenteric lymph 
nodes (MLNs) from G-MDSC exo-treated colitis mice. Moreover, lower serum levels of 
interferon (IFN)-γ and tumor necrosis factor (TNF)-α were detected in G-MDSC exo-
treated colitis mice. Interestingly, inhibition of arginase (Arg)-1 activity in G-MDSC 
exo partially abrogated the spontaneous improvement of colitis. In addition, G-MDSC 
exo could suppress CD4+ T cell proliferation and IFN-γ secretion in vitro and inhibit 
the delayed-type hypersensitivity (DTH) response, and these abilities were associated 
with Arg-1 activity. Moreover, G-MDSC exo promoted the expansion of Tregs in vitro. 
Taken together, these results suggest that G-MDSC exo attenuate DSS-induced colitis 
through inhibiting Th1 cells proliferation and promoting Tregs expansion.
INTRODUCTION
Inflammatory bowel disease (IBD) is a non-specific, 
inflammatory, autoimmune disorder with abdominal 
pain, diarrhea, and bloody stools that may lead to the 
development of cancer [1]. In humans, IBD includes 
ulcerative colitis (UC) and Crohn’s disease (CD) and is 
caused by the body’s immune response to the normal flora 
which should normally be tolerable and other factors of 
host [2]. Studies have shown that Th1 cells and secreted 
inflammatory factors promoted the development of IBD 
[3]. Hofseth and colleagues showed that resveratrol 
protected against DSS induced colitis mouse through up-
regulating the silent mating type information regulation-1 
(SIRT-1) of immune cells in the colon [4]. However, 
regulatory T cells (Tregs) play positive roles in maintaining 
intestinal immune balance [5]. Tregs are decreased in 
patients with IBD [6], resulting in an imbalance between 
pro-inflammatory Th1 cells and anti-inflammatory Tregs. 
The incidence of IBD is on the rise globally. Currently, IBD 
patients are treated symptomatically [7], and there is an 
urgent need for effective and curative medical treatments. 
MDSC are broadly considered as a heterogeneous 
population of immature myeloid cells that dampen the 
immune response and accumulate in pathological cases of 
tumor, inflammation and pathogen infection [8]. MDSC 
in mice are widely identified as Gr-1 (consisting of Ly6G 
and Ly6C markers) and CD11b double-positive cells. The 
two major populations of MDSC can be differentiated by 
morphologic characteristics and the expression of Gr-1 
molecule; CD11b+Ly6G+Ly6Clow cells with granulocyte-like 
morphology are defined as granulocytic MDSC (G-MDSC), 
and CD11b+Ly6G−Ly6Chigh cells with monocyte-like 
morphology are defined as monocytic MDSC (M-MDSC) 
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[9]. Both types expand greatly in different tumor models, and 
the number of G-MDSC is significantly higher than that of 
M-MDSC. Moreover, the immunosuppressive mechanism 
of G-MDSC is different from that of M-MDSC [10]. 
G-MDSC suppress innate and adaptive immune responses 
through mechanisms involving L-arginine metabolism and 
reactive oxygen species (ROS) production [11, 12]. These 
immunosuppressive roles of G-MDSC imply that they can 
be used to treat autoimmune diseases [13]. In fact, MDSC 
have been employed to treat collagen-induced arthritis 
(CIA) and showed a certain effect on reducing severity [14]. 
Ioannou and colleagues demonstrated that G-MDSC 
ameliorated experimental autoimmune encephalomyelitis 
through inhibition of encephalitogenic Th1 and Th17 
immune responses [15]. Another study showed that 
the increased elimination of G-MDSC was due to the 
extracellular trap (ET) formation driven by the inflammatory 
milieu of lupus and demonstrate the role of cytokines such 
as IFN-α, IFN-γ and IL-6 in the induction of ET released 
by G-MDSC correlated with the production of ROS [16]. 
However, the exact role of MDSC in IBD pathogenesis 
is unclear, and there are controversies regarding their 
immunosuppressive functions in this context [17, 18]. 
Exosomes (exo) are 30–150-nm phospholipid bilayer-
enclosed vesicles that are either released from the parental 
cell into the extracellular space when multivesicular 
bodies fuse with the plasma membrane or released 
directly from the plasma membrane [19]. One study 
demonstrated that almost all living cells can secrete exo, 
which are widely present in various biological fluids [20]. 
It is becoming increasingly clear that exo have specialized 
functions and play key roles in intercellular signaling, 
coagulation, and waste management [21]. Exo are also 
reportedly involved in immune response, apoptosis, 
angiogenesis, inflammation, and tumor development [22]. 
Consequently, there is growing interest in their clinical 
applications for therapy, prognosis, and disease and 
health biomarkers. From the perspective of disease 
prevention, exo exhibit more advantages than parental 
cells [23]. Firstly, exo storage and transport are simple, 
and they can be used with less cytotoxicity and biohazard. 
Secondly, the complex molecules on the surface of exo 
offer potential mechanisms of homing to specific tissues 
and microenvironments. Lastly, the therapeutic proteins 
and nucleic acids carried by exo are not easily degraded. 
Studies have demonstrated that immature dendritic 
cell-derived exo are a promising subcellular vaccine for 
autoimmunity, and exo released from iDCs secreting 
transforming growth factor (TGF)-β1 prevented the 
development of autoimmune diseases [24]. 
In this study, G-MDSC were sorted from the 
spleens of tumor-bearing mice, then G-MDSC exo were 
isolated from the culture supernatant of G-MDSC by serial 
centrifugation and purification with an isolation kit. We 
found that G-MDSC exo could attenuate DSS-induced 
colitis and restore intestinal immune balance. Subsequently, 
we confirmed that G-MDSC exo suppress CD4+ T cell 
proliferation and the delayed-type hypersensitivity (DTH) 
response, and these roles were partially related to arginase 
(Arg)-1 activity. Moreover, G-MDSC exo could promote 
Tregs expansion in vitro. Collectively, these data indicate 
that G-MDSC exo have a strong ability to reduce the severity 
of DSS-induced colitis. Our findings provide a potential 
immunotherapy for IBD and other autoimmune diseases.
RESULTS
Extraction and identification of G-MDSC exo
G-MDSC were isolated from the spleen of tumor-
bearing mice and analyzed by FCM; cell purity was 
> 95% (Figure 1A). We could acquire 1 × 107 G-MDSC 
from one tumor-bearing mouse. G-MDSC were cultured 
in vitro, and culture supernatants were collected after 20 h. 
Exosomes in the supernatants were purified by the method 
of differential centrifugation followed by use of exosomes 
extraction kits. G-MDSC exo were observed by transmission 
electron microscopy, which revealed that most of the 
exosomes displayed closed round vesicles with diameters 
of 30–150 nm (Figure 1B and 1C). Further characterization 
indicated that G-MDSC exo had a similar level of exo-
associated CD63 (Figure 1D). In contrast, calnexin was 
not detected in the purified G-MDSC exo preparations 
(Figure 1D), indicating that G-MDSC exo were free from 
contamination with non-exo membrane proteins. We could 
acquire 3–5 µg G-MDSC exo from 1 × 106 G-MDSC.
Arg-1 is one of the most important molecules that 
plays a critical role in the immunosuppressive function of 
G-MDSC. To determine whether G-MDSC exo contain 
Arg-1 activity, the Arg-1 activity of G-MDSC exo was 
detected with an assay kit according to the manufacturer’s 
instructions. The results showed Arg-1 activity in 
G-MDSC exo (Figure 1E). Additionally, the specific 
arginase inhibitor Nω-hydroxy-nor-Arginine (nor-NOHA, 
also NN) was added to the G-MDSC culture system, and 
this type of exo was isolated and termed (G-MDSC+NN) 
exo; they showed significant decrease of Arg-1 activity 
(Figure 1E).
G-MDSC exo attenuate DSS-induced 
experimental colitis in mice
To test whether G-MDSC exo can ameliorate colitis, 
C57BL/6 mice were injected i.p with G-MDSC exo 
(30 μg/mouse/injection) on days 2, 4, and 6 after colitis 
induction. Multiple observations collectively indicated that 
G-MDSC exo-treated mice were considerably less susceptible 
to DSS-induced colitis compared to other groups. Firstly, the 
DAI of G-MDSC exo-treated colitis mice was lower than 
in colitis mice or (G-MDSC+NN) exo-treated colitis mice 
on day 4 after the initiation of DSS treatment. Moreover, 
this difference gradually increased over time (Figure 2A). 
Oncotarget15358www.impactjournals.com/oncotarget
Secondly, DSS treatment caused severe bloody stools that 
persisted until the sacrifice of colitis mice or (G-MDSC+NN) 
exo-treated colitis mice. This change was not observed in 
G-MDSC exo-treated colitis mice (Figure 2B). Thirdly, 
we measured the length of colon from mice in different 
groups. Results showed that the length of colon in colitis 
mice or (G-MDSC+NN) exo-treated colitis mice is shorter 
than G-MDSC exo-treated colitis mice (Figure 2C). Finally, 
histologic examination of colonic sections revealed complete 
disruption of the colonic architecture in colitis mice, whereas 
G-MDSC exo-treated colitis mice retained intact colonic 
architecture, and the severity of disease in (G-MDSC+NN) 
exo-treated colitis mice was greater than G-MDSC exo-
treated colitis mice (Figure 2D). Consistent with histologic 
observations, the histologic scoring of G-MDSC exo-
treated colitis mice was significantly lower than colitis mice, 
G-MDSC exo-treated colitis mice or (G-MDSC+NN) exo-
treated colitis mice (Figure 2E). Taken together, these results 
strongly support the hypothesis that G-MDSC exo could 
attenuate DSS-induced murine experimental colitis and 
suggest that Arg-1 plays an important role in this process.
G-MDSC exo prevent Th1 cell development 
and promote Tregs expansion in murine 
experimental colitis
Th1 cells and IFN-γ are crucial for the pathogenesis of 
IBD, and TNF-α also participates in IBD pathogenesis [25]. 
However, Tregs could maintain the intestinal immune 
balance and play a protective role in IBD [5]. To understand 
the mechanisms underlying the action of G-MDSC exo 
against colitis, the percentages of Tregs and Th1 cells in 
MLNs were analyzed by FCM, and the serum levels of 
IFN-γ and TNF-α were determined by ELISA. As shown 
in Figure 3A, following treatment with G-MDSC exo, 
the percentage of Th1 cells was significantly lower than 
that in colitis, Neu exo-, or (G-MDSC+NN) exo-treated 
colitis mice. However, the percentage of Tregs in G-MDSC 
exo-treated colitis mice was significantly higher than that 
in colitis or Neu exo-treated colitis mice (Figure 3B). 
Moreover, markedly lower levels of IFN-γ and TNF-α 
were detected in the serum of G-MDSC exo-treated colitis 
mice compared with that in other groups of colitis mice 
Figure 1: Extraction and identification of G-MDSC exo. (A) Immunomagnetic beads were used to sort G-MDSC from the spleens 
of tumor-bearing mice. Ly-6G and CD11b expression levels were analyzed by FCM. (B) Representative transmission electron micrograph 
of G-MDSC exo (magnification, × 80,000; scale bar = 100 nm). (C) The particle-size distribution of G-MDSC exo dispersed in fluid. 
(D)CD63 and calnexin expressions were detected by western blot. Data shown in A, B, and D are from one of three independent experiments. 
(E)Exosome Arg-1 activity was detected with an Arg-1 activity assay kit. In the inhibition assay, G-MDSC were treated with the inhibitor 
nor-NOHA. Data are shown as the mean ± SEM of each group (n = 6) pooled from three independent experiments. **p < 0.01, ***p< 0.001, 
analyzed by ANOVA and Q test.
Oncotarget15359www.impactjournals.com/oncotarget
Figure 2: G-MDSC exo attenuate the severity of DSS-induced colitis. Murine experimental colitis was induced in C57BL/6 
mice (n = 10/group) by providing 2.5% DSS solution in their drinking water for 10 days. Mice received i.p. injections with exosomes 
(30 μg/mouse/injection) on days 2, 4, and 6. (A) Disease activity was determined daily as described in the methods. Mice were sacrificed on 
day 8 by eye bloodletting followed by cervical dislocation. Colon sections obtained from mice were analyzed for their outward appearance 
(B), length (C), degree of inflammation (D) and H & E histologic scoring. (E) All data are presented as the mean ± SEM from one of 
three independent experiments. *p < 0.05, **p < 0.01; 1, G-MDSC exo-treated colitis mice versus colitis mice; 2, G-MDSC exo-treated 
colitis mice versus (G-MDSC+NN) exo-treated colitis mice, analysis with ANOVA and Q test. The mice of the control group had no DSS 
treatment. The mice of the colitis group had DSS treatment, while no exo treatment. All other experimental groups had DSS and different 
exos treatment.
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Figure 3: G-MDSC exo prevent the Th1 cell response and expand Tregs in murine experimental colitis. Mice were 
sacrificed, and lymphocytes from the MLNs of different groups of DSS-induced colitis mice were isolated on day 8. (A) For Th1 cell 
detection, lymphocytes were stimulated for 5 h with 1 µg/ml ionomycin and 50 ng/ml phorbol myristate acetate in the presence of 2 mg/ ml 
monensin at 37°C and stained with anti-mouse CD4 and IFN-γ mAbs according to the manufacturer’s protocols. The percentage of Th1 
cells was analyzed by FCM (left), and the statistical analysis results are shown (right). (B) For the detection of Tregs, lymphocytes were 
stained with anti-mouse CD4, CD25, and Foxp3 mAbs as described in the methods. The percentage of Tregs was analyzed by FCM (left), 
and the statistical analysis results are shown (right). (C) Serum cytokine concentrations in different groups after 8 days of DSS treatment. 
Data are shown as the mean ± SEM of each group (n = 10) pooled from three independent experiments. *p < 0.05, **p < 0.01, ns: not 
significant, analyzed by ANOVA and Q test.
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(Figure 3C). Hence, our data indicate that treatment with 
G-MDSC exo inhibits Th1 cell responses but enhances 
Tregs, which contributes to the inhibition of colitis. 
G-MDSC exo suppress CD4+ T cell proliferation 
and IFN-γ secretion in vitro
Based on the immunosuppressive effect of 
G-MDSC exo on Th1 cells in DSS-induced murine 
colitis, we examined the role of G-MDSC exo in CD4+ T 
cell proliferation and IFN-γ secretion from CD4+ T cells 
in vitro. Moreover, we observed the role of Arg-1 activity in 
the immunosuppression of G-MDSC exo. In the presence 
of anti-CD3 and anti-CD28 mAbs, CD4+ T cells isolated 
from the spleen of male wild-type C57BL/6 mice were 
cultivated in the presence of varying concentrations of 
G-MDSC exo or equimolar concentrations of Neu exo for 
3 days. The CPM values in G-MDSC exo-treated groups 
were lower than in the untreated or Neu exo-treated groups, 
and the degree of CPM value reduction in G-MDSC exo-
treated groups correlated with the amount of G-MDSC 
exo (Figure 4A). However, the CPM values in medium 
and high concentrations (G-MDSC+NN) exo-treated 
groups were significantly lower than those of G-MDSC 
exo-treated groups (Figure 4B). Notably, the changes of 
IFN-γ levels in culture supernatants were consistent with 
the changes of CD4+ T cell proliferation in different groups 
(Figure 4C and 4D). These results confirmed that G-MDSC 
exo suppressed CD4+ T cell proliferation and IFN-γ 
secretion in a dose-dependent manner, and this inhibitory 
effect correlated with Arg-1 activity.
G-MDSC exo suppress DTH response 
The DTH reaction mainly correlated with Th1 cells. 
To further confirm the role of G-MDSC exo in suppressing 
the response of CD4+ T cells in vivo, we investigated the 
role of G-MDSC exo in DTH. The DTH model involved 
an OVA challenge in mouse footpads, and footpad 
swelling was measured at a given time after the challenge. 
The DTH response was significantly suppressed in mice 
treated with G-MDSC exo before the OVA challenge 
(Figure 5). Moreover, this effect was weakened in 
(G-MDSC+NN) exo-treated mice (Figure 5).
G-MDSC exo promote TGF-β-induced Tregs 
generation from CD4+ T cells in vitro
Given the effect of G-MDSC exo on Tregs expansion 
in murine IBD and previous reports indicated that MDSC 
Figure 4: G-MDSC exo suppress CD4+ T cell proliferation and IFN-γ secretion correlating with Arg-1 activity in vitro. 
(A and B). G-MDSC exo suppress CD4+ T cell proliferation through Arg-1 activity. CD4+ T cells were treated with G-MDSC exo (A) or/
and (G-MDSC+NN) exo (B) at different concentrations for 72 h. The cultivation system was stimulated with anti-CD3 mAb (2 µg/ml) and 
anti-CD28 mAb (2 µg/ml). Cell proliferation was measured by [3H]-thymidine incorporation. (C and D). G-MDSC exo suppress IFN-γ 
secretion through Arg-1 activity. The levels of IFN-γ in culture supernatants from the CD4+ T cell proliferation system were detected using 
sandwich ELISAs. Data are shown as the mean ± SEM of each group (n = 6) pooled from three independent experiments. *p < 0.05, 
**p < 0.01, analyzed by ANOVA and Q test.
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promoted Tregs expansion [26, 27]. We assumed that G-MDSC 
exo might promote the generation of Tregs from CD4+ T cells. 
To test this hypothesis, we evaluated the influence of G-MDSC 
exo on the expansion of Tregs from CD4+ T cells. CD4+ T cells 
isolated from C57BL/6 mice splenocytes were cultured for 72 h 
in the presence or absence of exo isolated from G-MDSC 
or neutrophils. Tregs percentages were determined by FCM. 
As shown in Figure 6A and 6B, a significant dose-dependent 
increase in Tregs percentage was observed in the presence of 
G-MDSC exo.  
DISCUSSION
Exosomes are highly abundant in biologic fluids 
where they transfer information between cells. A report 
showed that MDSC isolated from BALB/c mice carrying 
4T1 mammary carcinomas shed exosomes that contain 
multiple bioactive components derived from many 
subcellular compartments and are associated with diverse 
functions [22]. In this study, we found G-MDSC exo were 
bilayered vesicles as having diameters in the 30–150-nm 
range by transmission electron micrographs, which is 
consistent with previously described exosomes [28]. It is 
noteworthy that G-MDSC exo possess Arg-1 activity, which 
plays a critical role in the immunosuppressive function of 
G-MDSC. Overall, these results indicate that G-MDSC exo 
share some biological functions with their parental cells. 
Although studies have attempted to utilize MDSC 
to suppress the autoimmune response and limit tissue 
injury in the context of EAE [15, 29] and CIA [14, 30], 
and get beneficial results. However, the roles of MDSC 
in IBD pathogenesis remain unclear, and the reports 
of immunosuppressive functions of MDSC in IBD are 
fairly controversial [17, 18]. Haile et al showed that 
MDSC frequency dramatically increased during intestinal 
inflammation in a CD8+ T-cell-mediated mouse model 
of IBD and suppressed IFN-γ secretion from T cells, and 
transferred MDSC decreased intestinal inflammation [31]. 
Recruited myeloid cells may acquire antigen-presenting 
functions after undergoing a series of phenotypic and 
functional changes and stimulate cytokine production by 
effector Th1/Th17 cells in chronic colitis [32]. Moreover, 
inflammatory monocytes recruited in the lamina propria 
of colon may differentiate into proinflammatory dendritic 
cells [33]. However, these cells express inducible nitric 
oxide synthase and Arg-1, suggesting a more activated 
state resulting in an inability to suppress activated/
effector Th1/Th17 cells [34]. Considering the exact role 
of MDSC in IBD pathogenesis is unclear, and the clear 
immunosuppression and rich content of G-MDSC in 
tumor-bearing mice, we used G-MDSC exo to inhibit the 
development of DSS-induced colitis. The application of 
G-MDSC exo attenuated DSS-induced colitis, which was 
accompanied by a decrease in the number of Th1 cells and 
an increase in the number of Tregs from MLNs. Moreover, 
G-MDSC exo reduced the serum levels of IFN-γ and 
TNF-α in DSS-induced colitis mice. Inhibition of Arg-1 
activity with nor-NOHA partly attenuated the improvement 
of DSS-induced colitis by G-MDSC exo. G-MDSC play 
the role of immune suppression by the production of 
ROS, Arg-1 and generation of NO [10]. Peroxynitrite 
which formed by the cooperative activity of ROS with 
NO is another factor that inhibits effector T cells [35]. 
Peroxynitrite leads to the nitration of tyrosines in the T-cell 
Figure 5: G-MDSC exo suppress the DTH reaction in an Arg-1-dependent manner. OVA-sensitized mice were challenged 
with OVA in the footpads, and paw edema was measured at 24, 48, and 72 h after the challenge. Footpad swelling was calculated according 
to the formula described in the methods. Data are shown as the mean ± SEM of each group (n = 6) pooled from three independent 
experiments. *p < 0.05, **p < 0.01; 1, G-MDSC exo-treated DTH mice versus DTH mice; 2, G-MDSC exo-treated DTH mice versus 
(G-MDSC+NN) exo-treated DTH mice, analyzed by ANOVA and Q test.
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receptor (TCR). This reaction damages the conformational 
flexibility of TCR complex, and inhibits its binding with 
peptide-loaded MHC and leads to the unresponsiveness 
of T cells to antigen-specific stimulation [8, 15, 36, 37]. 
The suppressive activity of Arg-1 is based on its role in the 
hepatic urea cycle, metabolizing L-arginine to L-ornithine. 
Expression of Arg-1 has been reported to decrease CD3ξ-
chain biosynthesis and down-regulate TCR on cell surface 
and leads to the unresponsiveness of T cells without MHC 
II restriction and in an antigen-non-specific manner [38]. 
In our study, G-MDSC exo mediate their suppressive 
activity on autoimmune IBD mice through preventing 
Th1 cell reaction which depended on Arg-1 activity. 
These regulation on T effector immune responses without 
MHC II restriction and in an antigen-non-specific manner. 
Collectively, these results showed that G-MDSC exo can 
inhibit DSS-induced colitis, and this was associated with 
Arg-1 activity-mediated suppression of Th1 cells and Tregs 
expansion.
To demonstrate the immunosuppressive effect 
of G-MDSC exo, we observed the roles of G-MDSC 
exo on CD4+ T cell proliferation and Tregs expansion 
in vitro. We found that G-MDSC exo could inhibit CD4+ 
T cell proliferation and IFN-γ secretion, and these effects 
correlated with Arg-1 activity. Moreover, these effects were 
further confirmed by our observation that G-MDSC exo 
alleviated the DTH reaction in vivo. In addition, we found 
G-MDSC exo promoted Tregs expansion from CD4+ T cells 
in the presence of TGF-β, although the exact reasons need 
further study. One certainty is that MDSC promote Tregs 
expansion [26, 27, 39]. This is consistent with the theory 
that exosomes have some properties in common with 
their parent cells. These experimental results suggested 
G-MDSC exo have strong immunosuppressive activity 
in vitro and are consistent with the roles of G-MDSC exo 
in DSS-induced colitis.
In conclusion, we successfully isolated and identified 
G-MDSC exo, providing an experimental basis for further 
Figure 6: G-MDSC exo promote TGF-β induced Tregs generation from CD4+ T cells. 1.5 × 106/ml CD4+ T cells were isolated 
from the spleen of C57BL/6 mice and cultured for 72 h with anti-CD3 (2 μg/ml), anti-CD28 (2 μg/ml) Ab, and TGF-β (5 ng/ml) in the 
presence or absence of exo isolated from G-MDSC or neutrophils. The cells were stained with anti-mouse CD4, CD25, and Foxp3 mAbs. 
The cells were gated first on living lymphocytes and then CD4+ T cells. Tregs percentages were analyzed by FCM. Representative dot plots 
of Tregs (A) and the percentages of Tregs from different treatments (B). Data are shown as the mean ± SEM of each group (n = 6) pooled 
from three independent experiments, analyzed by ANOVA and Q test.. *P < 0.05; **P < 0.01.
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studies. Our findings suggest that G-MDSC exo attenuate 
DSS-induced murine colitis by suppressing pathogenic Th1 
cells and inducing Tregs differentiation and the protective 
effect correlated with arginase activity in MDSC exo. 
Moreover, these immunosuppressive effects of G-MDSC 
exo were confirmed in vitro. In conclusion, our work 
provides a new way in the development of an effective 
intervention of IBD and other autoimmune diseases.
MATERIALS AND METHODS
Antibodies and reagents
CD4+ T cells, G-MDSC isolation kits, and 
phycoerythrin (PE)-conjugated anti-mouse interferon 
(IFN)-g were from Miltenyi Biotec (Bergisch Gladbach, 
Germany). PE, fluorescein isothiocyanate (FITC), PE-Cy5-
conjugated anti-mouse CD4 mAb (L3T4), PE-conjugated 
anti-mouse Foxp3 mAb (FJK-16s), and Cy5.5-conjugated 
anti-mouse CD25 mAb (PC61.5) were from eBioscience 
(San Diego, CA, USA). PE-conjugated anti-mouse Ly-6G 
mAb (RB6–8C5), CD11b mAb (M1/70), anti-CD3 mAb, 
and anti-CD28 mAb were from Biolegend (San Diego, CA, 
USA). Mouse mAbs against CD63 (Y-18) and calnexin (C8. 
B6) were from Abcam (Cambridge, UK). IFN-g and tumor 
necrosis factor (TNF)-α enzyme-linked immunosorbent 
assay (ELISA) kits were from MultiSciences (Shanghai, 
China). QuantiChromTM arginase assay kits were from 
Bioassays (Hayward, CA, USA). ExoQuick-TCTM 
Exosomes were from SBI (Mountain View, CA, USA). 
Recombinant mouse TGF-β was from PeproTech (Rocky 
Hill, NJ, USA). MicroBCA protein assay kits were from 
Beijing ComWin Biotech (Beijing, China). Ovalbumin 
(OVA) and complete Freund’s adjuvant (CFA) were from 
Sigma (St. Louis, MO, USA). Nω-hydroxy-nor-Arginine 
was from Cayman (Ann Arbor, MI, USA).
Mice
Male C57BL/6 mice (6–8 weeks old, weighing 
18–22 g) were from the Animal Research Center of 
Jiangsu University (Zhenjiang, China) and were housed 
in a specific pathogen-free facility. The experimental 
protocols were approved by the Jiangsu University Animal 
Ethics and Experimentation Committee.
G-MDSC isolation
Tumor-bearing mice were established with the Lewis 
lung adenocarcinoma cell line according to a method 
previously used in our laboratory [9, 40]. When tumors were 
greater than 2 cm in diameter, G-MDSC were harvested 
from the spleen with G-MDSC isolation kits according 
to the manufacturer’s instructions, and their purity was 
assessed by measuring the expression of Ly-6G and CD11b 
with flow cytometry (FCM).
G-MDSC exo purification
To make preparations for large-scale exosomes 
purification, isolated G-MDSC were cultivated in an 
incubator at 37°C and 5% CO
2
 for 20 h in G-MDSC-
conditioned medium (R1640 with 10% fetal bovine serum 
that had been ultracentrifuged at 100,000 g for 16 h at 4°C). 
The culture supernatant of G-MDSC was harvested after 
20 h. Exosomes were purified from the supernatant by 
differential centrifugation and ultrafiltration membrane 
technology followed by the use of an exosomes extraction 
kit. In brief, cells and cellular debris were removed by 
sequential centrifugation at 500 g for 10 min, 1000 g 
for 30 min, and 10000 g for 30 min. The concentrated 
supernatant was acquired by an ultrafiltration membrane 
with a molecular weight cut-off ranging from 2 to 100 kDa. 
The supernatant was passed through a 0.22-μm 
microcentrifuge filter. The filtrate was mixed with 
exosomes isolation reagent (v/v = 5:1) and incubated 
for 16 h at 4°C. Finally, the mixture was centrifuged at 
1000 g for 30 min, and the precipitate was G-MDSC 
exo. Exosomes were dissolved in phosphate-buffered 
saline (PBS) and stored at −80°C. The protein contents of 
G-MDSC exo were quantified using a microBCA protein 
assay kit. In this study, we also prepared neutrophil-
derived exo (Neu exo), which served as control for 
G-MDSC exo.
In the purification process of (G-MDSC+NN) 
exo in which the Arg-1 activity is inhibited, G-MDSC 
used to extract exosomes were cultured in the presence 
of 200 µM nor-NOHA, which is a potent inhibitor of 
arginase. Because nor-NOHA is dissolved in dimethyl 
sulfoxide (DMSO), we prepared (G-MDSC+DMSO) exo 
as solvent to control for the influence of DMSO on the 
experiment.
G-MDSC exo transmission microscopic 
examination
Purified G-MDSC exo suspended in 2% glutaraldehyde 
in PBS were loaded on a formvar-coated grid and negatively 
stained with 3% (w/v) aqueous phosphotungstic acid for 
1 min. Electron micrographs were observed by transmission 
electron microscopy (Tecnai-12; Philips, Amsterdam, 
Netherlands).
Western blot analysis 
G-MDSC and G-MDSC exo were lysed in 
radioimmunoprecipitation (RIPA) buffer, and lysates were 
separated by 12% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and subsequently 
electrotransferred onto Immobilon polyvinylidene 
membranes (Bio-Rad, Hercules, CA, USA), and probed 
with mouse mAbs against CD63 or calnexin, and HRP 
conjugated anti-mouse IgG followed by chemiluminescent 
detection (Champion Chemical, Whittier, CA, USA).
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Detection of arginase activity
Arg-1 activity contents in the lysates from exosomes 
or G-MDSC were measured by Arg-1 activity assay 
according to the manufacturer’s protocols. Briefly, 2 × 106 
G-MDSC or exosomes isolated from 2 × 106 G-MDSC or 
neutrophil were lysed in 50 µl RIPA buffer, collected the 
lysate by centrifugation at 14000 g for 10 min at 4°C, and 
added ddH
2
O to 100 µl. Arginase activity was detected 
with the QuantiChrom Argianse Assay kit (BioAssay 
systems, Hayward, CA) following the manufacturer’s 
instructions. 
DSS-induced experimental colitis in mice
DSS-induced murine experimental colitis was 
established as described previously with minor modification 
[41]. Briefly, male C57BL/6 mice were treated with 
2.5% DSS in drinking water for 10 days to induce colon 
injury and colitis, and these mice were treated with PBS 
or exosomes (30 µg/mouse/i.p) on days 2, 4, and 6 after 
DSS drinking. Normal control mice were given normal 
drinking water and were treated with PBS. Weight loss, 
rectal bleeding and diarrhea were monitored daily for 
10 days and graded separately on scales of 0–4. The average 
of the three values constitutes the disease activity index 
(DAI). Mice were sacrificed on day 8 by eye bloodletting 
followed by cervical dislocation. Colons were mechanically 
isolated, cleaned, and measured in length. After removing 
caecum and adipose tissue, the colons were fixed in 10% 
formalin solution, paraffin-embedded, sections, stained with 
hematoxylin and eosin (H & E), and examined under a light 
microscope. Histological scoring was done as described 
previously [42]. 
FCM analysis 
On day 8, mice were sacrificed by eye bloodletting 
followed by cervical dislocation. MLNs were isolated and 
grinded in 2 ml PBS. The cell suspensions were filtered 
through 70 µm cell strainers. The lymphocytes were 
collected by centrifugation at 500 g for 5 min at 4°C. 
For Tregs detection, lymphocytes were stained with anti-
mouse CD4 and CD25 and Foxp3 mAbs, and defined the 
proportion of CD25+Foxp3+ lymphocytes gated in CD4+ 
lymphocytes as described previously [43]. For the detection 
of Th1 cells, single-cell suspensions were stimulated 
with 50 ng/ml phorbol myristate acetate, 1 µg/ml 
ionomycin, and 2 µg/ml monensin. After 5 h, cells 
were stained with anti-CD3 and anti-CD4 mAbs, fixed, 
permeabilized, and stained with anti-IFN-γ mAb according 
to the intracellular staining kit (Invitrogen, Carlsbad, CA, 
USA) instructions. Defined the proportion of CD4+IFN-γ+ 
lymphocytes gated in CD3+ lymphocytes. 
ELISA
On day 8, mice were sacrificed by eye bloodletting 
followed by cervical dislocation. The eyeball blood was 
collected into 1.5 ml EP tubes without anticoagulant 
and the serum was isolated by centrifugation for 5 min 
at 3000 rpm. IFN-γ and TNF-α contents in the serum 
from different groups of mice were detected with the 
Mouse IFN-γ or TNF-α SunnyELISA Assay kit (Multi 
sciences, Hangzhou, China) following the manufacturer's 
instructions. 
T-cell proliferation assay
For in vitro experiments, CD4+ T cells were isolated 
from the splenocytes of wild-type C57BL/6 mice with 
a CD4+ T cell isolation kit as previously described [44]. 
Briefly, 1 × 106/ml cells were stimulated with anti-CD3 
(5 µg/ml) and anti-CD28 (1 µg/ml) mAbs in triplicate in 
round-bottom 96 wells. Different doses of each type of 
exosomes were added into the wells. Cells were cultured 
in a humidified 5% CO
2
 atmosphere at 37°C for 72 h, and 
[3H]-thymidine (1 µCi/well; Pharmacia, Uppsala, Sweden) 
was added for the last 16 h. The counts per minute (CPM) 
values of various wells were detected with an LS6500 
multi-purpose scintillation counter (Beckman Coulter, 
Brea, CA, USA).
Induction of CD4+CD25+Foxp3+ Tregs
CD4+ T cells isolated from C57BL/6 mice splenocytes 
were cultured with anti-CD3 and anti-CD28 mAbs in the 
presence or absence of 5 ng/ml TGF-β in a 24-well plate 
for 72 h in complete RPMI medium (1.5 × 106 cells/well) 
with or without exo isolated from G-MDSC or neutrophils. 
The percentages of CD25+Foxp3+ cells in CD4+ T cells were 
determined by FCM after 72 h.
Induction of DTH
DTH was induced in mice by challenging the footpad 
of previously sensitized mice with OVA as described 
previously [45]. In brief, C57BL/6 mice were sensitized 
by intradermal injections of 1 mg/ml CFA-emulsified 
OVA peptide (grade V) in a final volume of 200 µl 
at the tail base and back. Seven days after sensitization, 
each mouse was challenged by footpad injection of 20 
mg/ml PBS-dissolved OVA peptide (grade II) in a final 
volume of 30 µl. Another rear paw was injected with 
a comparable volume of PBS as a control. Footpad 
thickness was measured using a vernier caliper (Mitutoyo 
Corp, Tokyo, Japan) at a given time after the challenge. 
The magnitude of the DTH response was determined as 
follows: DTH units=(footpad thickness of OVA injection 
Oncotarget15366www.impactjournals.com/oncotarget
[mm])-(footpad thickness of PBS injection [mm]). For 
DTH treatment, mice were intraperitoneally (i.p.) injected 
with different exosomes (30 µg/mouse/injection) on days 
2, 4, and 6 after sensitization.
Statistical analysis 
The statistical significance of differences between 
groups was analyzed by ANOVA and Q test using the 
SPSS version 16.0 for Windows (SPSS Inc, Chicago, IL, 
USA). The data are presented as the mean ± SEM from at 
least three independent experiments. A p-value < 0.05 was 
considered statistically as significant.
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